Drug development of MET inhibitors: Targeting oncogene addiction and expedience

Paolo M. Comoglio, Silvia Giordano, Livio Trusolino

Research output: Contribution to journalArticle

Abstract

The MET tyrosine kinase stimulates cell scattering, invasion, protection from apoptosis and angiogenesis, thereby acting as a powerful expedient for cancer dissemination. MET can also be genetically selected for the long-term maintenance of the primary transformed phenotype, and some tumours appear to be dependent on (or 'addicted' to) sustained MET activity for their growth and survival. Because of its dual role as an adjuvant, pro-metastatic gene for some tumour types and as a necessary oncogene for others, MET is a versatile candidate for targeted therapeutic intervention. Here we discuss recent progress in the development of molecules that inhibit MET function and consider their application in a subset of human tumours that are potentially responsive to MET-targeted therapies.

Original languageEnglish
Pages (from-to)504-516
Number of pages13
JournalNature Reviews Drug Discovery
Volume7
Issue number6
DOIs
Publication statusPublished - Jun 2008

ASJC Scopus subject areas

  • Molecular Medicine
  • Drug Discovery

Fingerprint Dive into the research topics of 'Drug development of MET inhibitors: Targeting oncogene addiction and expedience'. Together they form a unique fingerprint.

  • Cite this